Company intelligence / Profile preview

Beijing Pearl Biotechnology Co., Ltd.

Beijing, China

Ownership: Private
Development stage: Phase 2

Overview

The company's lead product Vebreltinib (PLB-1001) received conditional approval from China's NMPA for MET exon 14 skipping NSCLC. The company has also submitted an NDA for Vebreltinib's new indication for NSCLC with MET amplification, which was granted priority review. Two indications of Vebreltinib were included in China's 2024 National Reimbursement Drug List.[2][3]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

PLB1001

Phase 2

Indications: Non-small cell lung cancer

2 more assets in the full pipeline.

Request access →

Partnerships

Apollomics Inc. (PLB1001/APL-101 partnership)[4]

Beyond the preview

Go deeper on Beijing Pearl Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Pearl Biotechnology Co., Ltd..

Explore the full profile